For the quarter ended June 2025, OrthoPediatrics (KIDS Quick QuoteKIDS - Free Report) reported revenue of $61.08 million, up 15.7% over the same period last year. EPS came in at -$0.11, compared to -$0.23 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $61.7 million, representing a surprise of -1%. The company delivered an EPS surprise of +35.29%, with the consensus EPS estimate being -$0.17.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how OrthoPediatrics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product sales by category- Trauma and deformity: $41.67 million versus the three-analyst average estimate of $44.58 million. The reported number represents a year-over-year change of +10.3%.
• Product sales by category- Sports medicine/other: $0.91 million compared to the $1.18 million average estimate based on three analysts. The reported number represents a change of -32.9% year over year.
• Product sales by category- Scoliosis: $18.52 million compared to the $15.95 million average estimate based on three analysts. The reported number represents a change of +35.4% year over year.

View all Key Company Metrics for OrthoPediatrics here>>>

Shares of OrthoPediatrics have returned -3.3% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.